Global Phase III program of Dance 501 in patients with type 1 and type 2 diabetes
Latest Information Update: 30 Jan 2020
At a glance
- Drugs Insulin (Primary)
- Indications Type 1 diabetes mellitus; Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Sponsors Aerami Therapeutics
- 24 Apr 2019 New trial record
- 23 Apr 2019 According to a Dance Biopharm media release, the company is planning to start Phase 3 clinical development program in mid-2020.